These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 26463234

  • 1. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.
    Kishan AU, Park SJ, King CR, Roberts K, Kupelian PA, Steinberg ML, Kamrava M.
    Br J Radiol; 2015; 88(1056):20150658. PubMed ID: 26463234
    [Abstract] [Full Text] [Related]

  • 2. Focal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs. conventional whole-gland treatment.
    Kamrava M, Chung MP, Kayode O, Wang J, Marks L, Kupelian P, Steinberg M, Park SJ, Demanes DJ.
    Brachytherapy; 2013; 12(5):434-41. PubMed ID: 23406987
    [Abstract] [Full Text] [Related]

  • 3. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Kole TP, Nichols RC, Lei S, Wu B, Huh SN, Morris CG, Lee S, Tong M, Mendenhall NP, Dritschilo A, Collins SP.
    Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
    [Abstract] [Full Text] [Related]

  • 4. From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis.
    Banerjee R, Park SJ, Anderson E, Demanes DJ, Wang J, Kamrava M.
    Brachytherapy; 2015 Jun; 14(3):366-72. PubMed ID: 25680768
    [Abstract] [Full Text] [Related]

  • 5. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.
    Widesott L, Pierelli A, Fiorino C, Lomax AJ, Amichetti M, Cozzarini C, Soukup M, Schneider R, Hug E, Di Muzio N, Calandrino R, Schwarz M.
    Int J Radiat Oncol Biol Phys; 2011 Aug 01; 80(5):1589-600. PubMed ID: 21167651
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
    Malone S, Croke J, Roustan-Delatour N, Belanger E, Avruch L, Malone C, Morash C, Kayser C, Underhill K, Li Y, Malone K, Nyiri B, Spaans J.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):725-32. PubMed ID: 22444999
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
    Fukuda S, Seo Y, Shiomi H, Yamada Y, Ogata T, Morimoto M, Konishi K, Yoshioka Y, Ogawa K.
    J Radiat Res; 2014 Nov 01; 55(6):1114-21. PubMed ID: 24957754
    [Abstract] [Full Text] [Related]

  • 12. A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma.
    Scobioala S, Kittel C, Elsayad K, Kroeger K, Oertel M, Samhouri L, Haverkamp U, Eich HT.
    Radiat Oncol; 2019 Aug 09; 14(1):143. PubMed ID: 31399115
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy.
    Al-Qaisieh B, Mason J, Bownes P, Henry A, Dickinson L, Ahmed HU, Emberton M, Langley S.
    Int J Radiat Oncol Biol Phys; 2015 Jul 15; 92(4):787-93. PubMed ID: 25936808
    [Abstract] [Full Text] [Related]

  • 17. Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.
    Ruggieri R, Naccarato S, Stavrev P, Stavreva N, Fersino S, Giaj Levra N, Mazzola R, Mancosu P, Scorsetti M, Alongi F.
    Br J Radiol; 2015 Oct 15; 88(1054):20140736. PubMed ID: 26235142
    [Abstract] [Full Text] [Related]

  • 18. Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?
    Dubouloz A, Rouzaud M, Tsvang L, Verbakel W, Björkqvist M, Linthout N, Lencart J, Pérez-Moreno JM, Ozen Z, Escude L, Zilli T, Miralbell R.
    Radiat Oncol; 2018 Jun 19; 13(1):114. PubMed ID: 29921291
    [Abstract] [Full Text] [Related]

  • 19. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D, Hopfgartner J, Gòra J, Kuess P, Kragl G, Berger D, Hegazy N, Goldner G, Georg P.
    Int J Radiat Oncol Biol Phys; 2014 Mar 01; 88(3):715-22. PubMed ID: 24521685
    [Abstract] [Full Text] [Related]

  • 20. VMAT vs. 7-field-IMRT: assessing the dosimetric parameters of prostate cancer treatment with a 292-patient sample.
    Kopp RW, Duff M, Catalfamo F, Shah D, Rajecki M, Ahmad K.
    Med Dosim; 2011 Mar 01; 36(4):365-72. PubMed ID: 21377863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.